Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

P3 Health Partners (PIII) EBITDA (2020 - 2025)

P3 Health Partners (PIII) has disclosed EBITDA for 6 consecutive years, with -$43.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 59.13% year-over-year to -$43.7 million, compared with a TTM value of -$331.0 million through Sep 2025, down 51.82%, and an annual FY2024 reading of -$318.3 million, down 92.15% over the prior year.
  • EBITDA was -$43.7 million for Q3 2025 at P3 Health Partners, down from -$33.5 million in the prior quarter.
  • Across five years, EBITDA topped out at -$12.7 million in Q1 2021 and bottomed at -$911.6 million in Q2 2022.
  • Average EBITDA over 5 years is -$128.1 million, with a median of -$43.5 million recorded in 2024.
  • The sharpest move saw EBITDA tumbled 3410.01% in 2022, then soared 97.76% in 2023.
  • Year by year, EBITDA stood at -$62.0 million in 2021, then plummeted by 764.78% to -$535.9 million in 2022, then surged by 93.21% to -$36.4 million in 2023, then crashed by 494.57% to -$216.3 million in 2024, then surged by 79.78% to -$43.7 million in 2025.
  • Business Quant data shows EBITDA for PIII at -$43.7 million in Q3 2025, -$33.5 million in Q2 2025, and -$37.5 million in Q1 2025.